FATE · CIK 1434316
What Fate Therapeutics, Inc. told the SEC could break it.
Fate's disclosures center on the fragility of its supply chain for an iPSC-derived cell-therapy pipeline. It produces all of its off-the-shelf cell product candidates at a single custom cGMP facility in San Diego, so a disruption there would impair its entire clinical supply, and it leans on third parties — sometimes a sole supplier — for certain manufacturing components and equipment, plus the monoclonal antibodies needed for combination-therapy trials. It also uses vendors located in or owned by Chinese companies for non-clinical and clinical trial support, exposing its trials to geopolitical disruption. As a clinical-stage company, its path to revenue ultimately depends on FDA approval of a BLA, which the agency could delay past its goal dates or decline.
4 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Geographic concentration
- single San Diego cGMP cell-manufacturing facilityhigh
Fate produces its iPSC-derived cell product candidates at a single custom-designed cGMP facility in San Diego, California; a disruption there would impair its entire clinical supply.
“Our manufacturing facility is located in San Diego, California, and is custom designed for the production of off-the-shelf cell product candidates using clonal master iPSC lines as the starting cell source.”
SEC filing →As of 2026 - reliance on China-based / Chinese-owned clinical-trial service vendorsmedium
Fate uses vendors located in China or owned/operated by Chinese companies for non-clinical and clinical trial support; geopolitical changes could disrupt its trials if those vendors can no longer provide services.
“We currently, and may in the future, do business with one or more companies located in China, or that are owned or operated by Chinese companies to provide non-clinical or clinical trial support services.”
Regulatory & policy
- FDA BLA approval risk (PDUFA review)medium
Fate's path to revenue depends on FDA BLA approval; the FDA may decide a BLA does not satisfy approval criteria and may miss PDUFA review goal dates, delaying or denying commercialization.
“Even if such data and information are submitted, the FDA may decide that the BLA does not satisfy the criteria for approval.”
SEC filing →As of 2026
Sole-source dependency
- sole third-party for certain components/equipment; monoclonal antibody dependencemedium
Fate relies on third parties for certain manufacturing components and may be limited to a sole supplier for some required components and equipment, and depends on availability of monoclonal antibodies for combination-therapy trials.
“Even if we are able to enter into such contracts, we may be limited to a sole third-party for the supply of certain required components and equipment.”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch